# CARTITUDE-6 (NCT05257083)

> A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05257083
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Stichting European Myeloma Network
- Conditions: Multiple Myeloma
- Interventions: Daratumumab; Bortezomib; Lenalidomide; Dexamethasone; Cilta-cel; Cyclophosphamide; Fludarabine
- Enrollment: 759
- Primary outcome: Progression free survival (PFS)
- Primary outcome: Sustained MRD-negative CR

## Commentary we found

- YouTube: 62
- Podcasts: 27
- X threads: 21
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cartitude-6-nct05257083

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05257083", "email": "<work email>"}; the inbox owner confirms by the emailed link.